Can-Fite BioPharma Ltd.CANFNYSE
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank57
3Y CAGR-53.2%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-53.2%/yr
vs +34.1%/yr prior
Acceleration
-87.3pp
Decelerating
Percentile
P57
Within normal range
vs 3Y Ago
0.1x
Contraction
Streak
2 yr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| 2024 | 3.11% |
| 2023 | -5.98% |
| 2022 | -18.26% |
| 2021 | 30.29% |
| 2020 | -3.66% |
| 2019 | -3.04% |
| 2018 | 7.13% |
| 2017 | 9.36% |
| 2016 | -0.12% |
| 2015 | -8.18% |